ACIU AC Immune SA

4.62
-0.1  -2%
Previous Close 4.72
Open 4.73
Price To Book 1.78
Market Cap 312137978
Shares 67,562,333
Volume 41,501
Short Ratio
Av. Daily Volume 408,137

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 data due 2020.
RG6100 (Anti-Tau RO7105705)
Alzheimer’s disease
Phase 1/2 interim high dose cohort data due 1H 2019, low dose cohort data due 2019.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease
Phase 2 trial planned for 1H 2019.
ACI-35
Alzheimer’s disease

Latest News

  1. What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own?
  2. Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
  3. AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
  4. AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
  5. Lilly (LLY) Signs New Immunology Deal With Private Biotech
  6. New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
  7. What Makes AC Immune (ACIU) a New Buy Stock
  8. AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
  9. AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
  10. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  11. Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
  12. What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
  13. AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
  14. AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
  15. AC Immune Enters Oversold Territory
  16. Why AC Immune SA Stock Crashed on January 30
  17. Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
  18. Roche Scraps Alzheimer's Test — But Investors Punished This Stock
  19. Roche, AC Immune drop Alzheimer drug trials after setback